Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

153 results about "Alpha-Tocopherol" patented technology

Α-Tocopherol is a type of vitamin E. It has E number "E307". Vitamin E exists in eight different forms, four tocopherols and four tocotrienols. All feature a chromane ring, with a hydroxyl group that can donate a hydrogen atom to reduce free radicals and a hydrophobic side chain which allows for penetration into biological membranes. Compared to the others, α-tocopherol is preferentially absorbed and accumulated in humans.

Methods of treating chronic inflammatory diseases using carbonyl trapping agents

InactiveUS6444221B1Improved therapeutic propertyImprove propertiesBiocidePeptide/protein ingredientsEtiologyBenzoic acid
These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., alpha-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).
Owner:SECANT PHARMA

Method for preparing cleavable polyethyleneglycol lipid derivates and application

InactiveCN101468203AEliminates conjugation stepsAchieve the goal of active targetingPharmaceutical non-active ingredientsLipid formationAlpha-Tocopherol
The present invention belongs to technical field of medicine, and relates to the preparing of cleavable polyethylene glycol (PEG) lipid derivative and an application thereof in the liquid particle preparation. The general formula is as follows: CH3O(CH2CH2O)n-R-O-R, n=5-5000. The molecular weight of PEG is 300-30000. R represents one group selected from hemisuccinate group and carbomethoxy. The liposoluble fragment represented by R comprises one component selected from cholesterol, sitosterol, alpha-tocopherol. According to the invention, polyethylene glycol are connected with lipoid derivatives such as cholesterol, alpha-tocopherol, etc. through ester linkage. The cleavable PEG lipid derivative can be applied to the modification of liquid particle preparation. On one hand, the PEG lipid derivative has appropriate adhesive force of the surface of liquid particle preparation and guarantees enough holding time of PEG lipid derivative in blood. On the other hand, the PEG lipid derivative can gradually break away from the surface of preparation in the circulation process. The particle preparation which only comprises a few polyethylene glycol on the surface can combine and phagocytose the pathological cell. The medicine is delivered into the cell and therefore has the function of selectively killing the pathological cell.
Owner:SHENYANG PHARMA UNIVERSITY

Soybean blending edible oil and preparation process thereof

The invention discloses soybean blending edible oil and a preparation process thereof. The soybean blending edible oil is prepared from the following raw materials in parts by weight: 100 parts of soybean oil, 20-30 parts of olive oil, 15-25 parts of grape seed oil, 10-20 parts of rosehip oil, 10-15 parts sea buckthorn oil, 6-10 parts of perilla seed oil, 1-7 parts of corn germ oil, and 0.1-0.2 part of a vegetable oil modifying agent; the vegetable oil modifying agent is prepared from the following ingredients in parts by weight: 2-3 parts of glucose oxidase, 3-4 parts of o-phosphoethanolamine, 0.8-1.2 parts of alpha-tocopherol, 0.6-1 part of a rosemary extract, 1-2 parts of lycopene, 0 .3-0.5 part of catechin and 0.4-0.6 part of phytic acid. The preparation process comprises the followingsteps of preparing the vegetable oil modifying agent, preparing compound vegetable oil and preparing the soybean blending edible oil. According to the soybean blending edible oil, the vegetable oil modifying agent is utilized to passivate lipoxygenase activity, prevent the browning reaction of soybean blending oil, reduce the content of dissolved oxygen and improve the oxidation resistance and thermal stability of blending oil so as to enable the blending oil to maintain good flavor and quality.
Owner:凤台县兴永食用油有限责任公司

Method for preparing low-benzopyrene high-purity d-alpha tocopherol acetate

The invention discloses a method for preparing low-benzopyrene high-purity d-alpha tocopherol acetate. The method comprises the following steps of: mixing d-alpha tocopherol, an inert organic solvent and a catalyst in a certain ratio, controlling the temperature, performing esterification reaction on the mixture and acetic anhydride, mixing obtained crude d-alpha tocopherol acetate and a polar solvent, loading to a column, adsorbing by using resin so as to remove impurities, mixing the obtained product and the inert organic solvent, adding a removal agent in a certain ratio, circulating at the constant temperature of 60 DEG C for 2 hours in an external circulation mode, filtering, concentrating, desolventizing, and performing short-path molecular distillation refinement under high vacuum conditions to obtain the low-benzopyrene high-purity d-alpha tocopherol acetate. The content of the obtained product is high, and the content of the d-alpha tocopherol acetate is more than or equal to 98 percent; the specific rotation is more than or equal to +24 degrees; the concentration of heavy metals (based on Pb) is less than or equal to 10ppm; and the concentration of benzopyrene is less than or equal to 2ppb. The quality of products meets the standards established by developed countries in Europe and America.
Owner:浙江伊宝馨生物科技股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products